biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > My Opinion of poof's Opinion of Chiesi's CHMP Opinion

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 24, 2023 9:18am

71 Views

Post# 35302975

RE:My Opinion of poof's Opinion of Chiesi's CHMP Opinion

"Poof reports that Chiesi has received an opinion, not an approval, an opinion, from CHMP. My opinion is that the opinion makes a thin soup. Approvals make positively hearty soups, fattening, even. It's also my opinion that poof's opinion about the CHMP opinion seems a little over the top, especially when he's still pumping the M&M, the Midatech "Merger"."

We will let you provide the industry data for the correlation between a positive CHMP opinion and ultimate European and FDA approval. The data is out there.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?